FertilityMaPreservFertiNCT07601451
Outcomes for Patients Who Preserved Their Fertility as Part of Cancer Treatment at the Center for the Study and Preservation of Eggs and Sperm: MaPreservFerti
An observational study of Fertility and Male Cancer, run by Hospices Civils de Lyon at 1 site in France.
Trial summary
Improvements in diagnostic methods and cancer treatments have led to a steady increase in survival rates. The 5-year survival rate for men diagnosed with cancer between the ages of 15 and 39 has exceeded 81%. As a result, quality of life-and in particular, addressing the issue of parenthood-has become essential. Read more about this study
- Who is it for?
- Ages 18 to 60 years, men only
- Conditions the study is for
- Fertility, Male Cancer, Oncofertility
- What is being tested?
- Patient self-assessment form
- How many people
- 950 participants
- Where
- 1 siteFrance
- Study dates
- Jun 2026to Jun 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- Men only
- No healthy volunteers
- Adult
Study population: Patients who undergone fertility preservation after gonadotoxic cancer treatments in the Lyon CECOS between 2010 and 2024.
Who may be able to join
- were between the ages of 18 and 60 at the time of fertility preservation
- Underwent fertility preservation at the CECOS in Lyon between January 1, 2010, and December 31, 2024.
- underwent fertility preservation in the context of cancer treatment
- who have indicated their consent to participate in the study by completing the questionnaire
Who cannot join
- Persons deprived of their liberty by a judicial or administrative decision
- Persons receiving psychiatric care
- Persons admitted to a health or social care facility for purposes other than research
- Adults subject to a legal protection measure (guardianship, conservatorship)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
CECOS, Hôpital Femme Mère Enfant
Bron, France, 69500
Eloïse FRAISON, Dr, 04 72 12 94 12 ext. +33, eloise.fraison@chu-lyon.fr
About this study
Official title: Outcomes for Patients Who Preserved Their Fertility as Part of Cancer Treatment at the Center for the Study and Preservation of Eggs and Sperm (CECOS) in Lyon Between 2010 and 2024: an Assessment of Male Parenthood. MaPreservFerti
Improvements in diagnostic methods and cancer treatments have led to a steady increase in survival rates. The 5-year survival rate for men diagnosed with cancer between the ages of 15 and 39 has exceeded 81%. As a result, quality of life-and in particular, addressing the issue of parenthood-has become essential.
Cancer treatments-surgery, radiation therapy, and chemotherapy-can significantly impair fertility. They may cause sexual dysfunction (anejaculation, anerection), androgen deficiency, or permanent impairment of spermatogenesis. Yet the desire for parenthood ranks among the top three life goals of patients newly diagnosed with cancer, and 50% of patients wish to have a child in the future. Preserving male fertility is therefore a crucial issue.
Read more
Before puberty, this can be done by taking a testicular tissue sample, although this is still considered experimental. After puberty, a sample taken from ejaculate allows for the storage of sperm straws.
Thus, when a couple wishes to conceive, following a potential reassessment of spermatogenesis if it is impaired, Assisted Reproductive Technology (ART) can be performed with or without the frozen sperm.
According to the literature, the sperm is typically used within 10 years of fertility preservation. Little data has been collected regarding whether men with a history of cancer conceive naturally or not. It is therefore important to gather this information regarding fatherhood, particularly whether men with a history of cancer have used ART or not, and whether frozen sperm was used or not, based on the results of the follow-up semen analysis performed after treatment.
Primary objective To describe fertility-whether spontaneous or following assisted reproductive technology (ART)-with or without the use of preserved gametes, among patients who underwent fertility preservation for cancer treatment at the CECOS in Lyon between 2010 and 2024.
Secondary objective:
To assess the population of men who preserved their fertility prior to cancer treatment at the Center for the Study and Preservation of Eggs and Sperm (CECOS) in Lyon between 2010 and 2024, specifically:
- The number and clinical and epidemiological characteristics of the patients.
- Describe post-cancer fertility
- Understand CECOS's care protocols to improve the patient care pathway.
- Describe the psychological difficulties at the time of collection that prevented the procedure and thus the preservation of fertility.
- Determine the fate of preserved straws that were not used
Methodology:
- Retrospective analysis of data from the CECOS in Lyon between 2010 and 2024.
- Information collected from the database: patient age, indication, type of fertility preservation performed (testicular tissue or ejaculate)
- Subsequently, a paper and electronic questionnaire was sent to these same patients to collect data on their fertility following fertility preservation.
- Information collected via the questionnaires: marital status, place of residence, paternity prior to cancer, type of cancer, treatment received, achievement of pregnancy after cancer and method (spontaneous pregnancy, reuse of straws at the center, or ART at another center), donation of gametes to research, or destruction if unused.
The CECOS in Lyon is an integral part of the Department of Reproductive Medicine and Biology at the Hopsices Civils de Lyon.
Population studied: This study focuses on patients with a history of cancer who underwent gonadotoxic treatment and preserved their fertility at the CECOS in Lyon between 2010 and 2024
Inclusion criteria:
This study will include patients who:
- were between the ages of 18 and 60 at the time of fertility preservation
- underwent fertility preservation at the CECOS in Lyon between January 1, 2010, and December 31, 2024.
- underwent fertility preservation in the context of cancer treatment
- who have indicated their consent to participate in the study by completing the questionnaire
Exclusion criteria:
- Persons deprived of their liberty by a judicial or administrative decision
- Persons receiving psychiatric care
- Persons admitted to a health or social care facility for purposes other than research
- Adults subject to a legal protection measure (guardianship, conservatorship)
Procedure:
An information sheet will be sent to patients regarding the analysis of their medical data collected during their care, along with a questionnaire (see attached questionnaire) for the collection of prospective data. The materials will be sent either by mail (with a stamped envelope for free return shipping as part of the study) or electronically via a dedicated and secure CECOS email address for email responses.
Number of subjects : 950 Study duration : 1 year
Study location : Center for the Study and Preservation of Eggs and Sperm (CECOS)
- Conditions
- Fertility, Male Cancer, Oncofertility
- Being tested
- Patient self-assessment form
- Keywords
- Male cancer treatment, Oncofertility, Male fertility preservation, Sperm cryopreservation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Patient self-assessment formOther
The self-assessment form will be sent only once. Patients will return it through a pre-stamped envelope joined to the form
| Study group | Role | What they receive |
|---|---|---|
| Targeted patients | Patients who undergone fertility preservation after gonadotoxic cancer treatments in the Lyon CECOS between 2010 and 2024 will receive a self-assessment form.
After completing it they will return it to the center for analysis Receives: Other: Patient self-assessment form |
What is being measured
The primary outcome is the main question the study is designed to answer.
The fertility of patients who underwent fertility preservation for cancer treatment at the CECOS in Lyon between 2010 and 2024.
It will be assessed based on the percentage of patients whose partners had a positive pregnancy test:
- either spontaneously after 12 months of unprotected intercourse
- or following Assisted Reproductive Technology (ART):
- with the use of cryopreserved gametes
- without the use of cryopreserved gametes, as a follow-up semen analysis allowed for the use of non-frozen gametes
- with the use of donor sperm.
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 May 2026
- Study startJun 2026 (estimated)
- Primary completionJun 2027 (estimated)
- Study completionJun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for FertilityStudies of the same condition, open and under way.
- More trials run by Hospices Civils de LyonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 950 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospices Civils de Lyon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07601451
- Sponsor's protocol ID
- 69HCL25_0974
- Other IDs
- 2025-A02363-46
- Acronym
- MaPreservFerti
- Status last verified
- May 2026
- First submitted
- 15 May 2026
- Last updated
- 22 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Outcomes for Patients Who Preserved Their Fertility as Part of Cancer Treatment at the Center for the Study and Preservation of Eggs and Sperm (CECOS) in Lyon Between 2010 and 2024: an Assessment of Male Parenthood. MaPreservFerti
- ClinicalTrials.gov ID
- NCT07601451
- Acronym / sponsor ID
- MaPreservFerti / 69HCL25_0974
- Conditions
- Fertility, Male Cancer, Oncofertility
- Keywords
- Male cancer treatment, Oncofertility, Male fertility preservation, Sperm cryopreservation
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 950 participants (estimated)
- Lead sponsor
- Hospices Civils de LyonUniversity, hospital or other
- Study start
- Jun 2026 (estimated)
- Primary completion
- Jun 2027 (estimated)
- Study completion
- Jun 2027 (estimated)
- First posted
- 22 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Improvements in diagnostic methods and cancer treatments have led to a steady increase in survival rates. The 5-year survival rate for men diagnosed with cancer between the ages of 15 and 39 has exceeded 81%. As a result, quality of life-and in particular, addressing the issue of parenthood-has become essential.
Cancer treatments-surgery, radiation therapy, and chemotherapy-can significantly impair fertility. They may cause sexual dysfunction (anejaculation, anerection), androgen deficiency, or permanent impairment of spermatogenesis. Yet the desire for parenthood ranks among the top three life goals of patients newly diagnosed with cancer, and 50% of patients wish to have a child in the future. Preserving male fertility is therefore a crucial issue.
Before puberty, this can be done by taking a testicular tissue sample, although this is still considered experimental. After puberty, a sample taken from ejaculate allows for the storage of sperm straws.
Thus, when a couple wishes to conceive, following a potential reassessment of spermatogenesis if it is impaired, Assisted Reproductive Technology (ART) can be performed with or without the frozen sperm.
According to the literature, the sperm is typically used within 10 years of fertility preservation. Little data has been collected regarding whether men with a history of cancer conceive naturally or not. It is therefore important to gather this information regarding fatherhood, particularly whether men with a history of cancer have used ART or not, and whether frozen sperm was used or not, based on the results of the follow-up semen analysis performed after treatment.
Primary objective To describe fertility-whether spontaneous or following assisted reproductive technology (ART)-with or without the use of preserved gametes, among patients who underwent fertility preservation for cancer treatment at the CECOS in Lyon between 2010 and 2024.
Secondary objective:
To assess the population of men who preserved their fertility prior to cancer treatment at the Center for the Study and Preservation of Eggs and Sperm (CECOS) in Lyon between 2010 and 2024, specifically:
- The number and clinical and epidemiological characteristics of the patients.
- Describe post-cancer fertility
- Understand CECOS's care protocols to improve the patient care pathway.
- Describe the psychological difficulties at the time of collection that prevented the procedure and thus the preservation of fertility.
- Determine the fate of preserved straws that were not used
Methodology:
- Retrospective analysis of data from the CECOS in Lyon between 2010 and 2024.
- Information collected from the database: patient age, indication, type of fertility preservation performed (testicular tissue or ejaculate)
- Subsequently, a paper and electronic questionnaire was sent to these same patients to collect data on their fertility following fertility preservation.
- Information collected via the questionnaires: marital status, place of residence, paternity prior to cancer, type of cancer, treatment received, achievement of pregnancy after cancer and method (spontaneous pregnancy, reuse of straws at the center, or ART at another center), donation of gametes to research, or destruction if unused.
The CECOS in Lyon is an integral part of the Department of Reproductive Medicine and Biology at the Hopsices Civils de Lyon.
Population studied: This study focuses on patients with a history of cancer who underwent gonadotoxic treatment and preserved their fertility at the CECOS in Lyon between 2010 and 2024
Inclusion criteria:
This study will include patients who:
- were between the ages of 18 and 60 at the time of fertility preservation
- underwent fertility preservation at the CECOS in Lyon between January 1, 2010, and December 31, 2024.
- underwent fertility preservation in the context of cancer treatment
- who have indicated their consent to participate in the study by completing the questionnaire
Exclusion criteria:
- Persons deprived of their liberty by a judicial or administrative decision
- Persons receiving psychiatric care
- Persons admitted to a health or social care facility for purposes other than research
- Adults subject to a legal protection measure (guardianship, conservatorship)
Procedure:
An information sheet will be sent to patients regarding the analysis of their medical data collected during their care, along with a questionnaire (see attached questionnaire) for the collection of prospective data. The materials will be sent either by mail (with a stamped envelope for free return shipping as part of the study) or electronically via a dedicated and secure CECOS email address for email responses.
Number of subjects : 950 Study duration : 1 year
Study location : Center for the Study and Preservation of Eggs and Sperm (CECOS)
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Targeted patients | – | Other: Patient self-assessment formPatients who undergone fertility preservation after gonadotoxic cancer treatments in the Lyon CECOS between 2010 and 2024 will receive a self-assessment form. After completing it they will return it to the center for analysis |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Patients who undergone fertility preservation after gonadotoxic cancer treatments in the Lyon CECOS between 2010 and 2024.
Key inclusion criteria (4 listed)
- were between the ages of 18 and 60 at the time of fertility preservation
- Underwent fertility preservation at the CECOS in Lyon between January 1, 2010, and December 31, 2024.
- underwent fertility preservation in the context of cancer treatment
- who have indicated their consent to participate in the study by completing the questionnaire
Key exclusion criteria (4 listed)
- Persons deprived of their liberty by a judicial or administrative decision
- Persons receiving psychiatric care
- Persons admitted to a health or social care facility for purposes other than research
- Adults subject to a legal protection measure (guardianship, conservatorship)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Patient self-assessment formThe self-assessment form will be sent only once. Patients will return it through a pre-stamped envelope joined to the form | Other | Targeted patients |
Primary outcome
The fertility of patients who underwent fertility preservation for cancer treatment at the CECOS in Lyon between 2010 and 2024.
Time frame: Day 1
It will be assessed based on the percentage of patients whose partners had a positive pregnancy test: * either spontaneously after 12 months of unprotected intercourse * or following Assisted Reproductive Technology (ART): * with the use of cryopreserved gametes * without the use of cryopreserved gametes, as a follow-up semen analysis allowed for the use of non-frozen gametes * with the use of donor sperm.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 May 2026.
Related trials for Fertility
Not yet recruiting
Application of Autologous Adipose Stromal Vascular Fraction in the Treatment of Diminished Ovarian Reserve
Diminished Ovarian Reserve (DOR)
Enrolling by invitation
Flo Digital Contraceptive Study
Contraception Use
RecruitingObservational study
Impact of Infertility on the Sexual Sphere in Couples Undergoing Assisted Reproduction
Sexual Health Quality of Life, Infertile Patients
Active, not recruiting
Ovarian Tissue Cryopreservation in Children
Cancer
Not yet recruitingObservational study
Perceptions and Acceptance of Grafting of Cryopreserved Testicular Tissue
Fertility, Testicular Tissue Cryopreserved
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Fertility and Male Cancer, run by Hospices Civils de Lyon at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 22 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Eloise FRAISON, Dr (04 72 12 94 12 ext. +33, Eloise.fraison@chu-lyon.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The fertility of patients who underwent fertility preservation for cancer treatment at the CECOS in Lyon between 2010 and 2024. (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2026.